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Objective: To assess the success and factors affecting early intrauterine device (IUD) provision after first trimester medical termination of
pregnancy (MTOP).
Study design: Subgroup analysis of a randomized contraceptive trial assessing the long-term effects of early provision of intrauterine
contraception following abortion. Altogether, 606 women undergoing MTOP were included and followed for 3 months. The intervention
group (n=307) was offered an IUD (either the levonorgestrel-releasing intrauterine system or copper-IUD) at a follow-up visit 1–4 weeks
after MTOP. The control group (n=299) contacted primary health care for follow-up and contraceptive provision. Adverse events (infections,
bleeding, residual tissue and incomplete abortion) were analyzed on intention-to-treat basis and IUD expulsions on per-protocol (PP) basis.
Results: In the intervention group, 234 women (76.2%) received the IUD as scheduled, 46 later (altogether 91.2%). In the control group, the
corresponding figures were 8 (2.7%) and 64 [altogether 24.1%, Odds ratio (OR) (95% Confidence interval (CI)) = 32.7 (20.3–52.6)]. Eighty-five
(27.7%)women in the intervention group and 38 (12.7%) in the control group received treatment (administration of antibiotics, misoprostol or surgical
evacuation) because of presumed adverse event [2.63 (1.72–4.01)],mainly residual tissue. In the control group, 23 (60.5%) of these occurred during the
first 2 weeks. IUD expulsion occurred in 12 (5.4%) of the 222 women in the intervention group (PP basis).
Conclusions: When provided as part of abortion service, most early insertions followingMTOPwere performed as planned. The main reason for
postponement was overdiagnosis of adverse events suspected at follow-up. The rate of IUD expulsion was similar to that reported previously.
Implications: Early insertion following MTOP is safe, and the rate of IUD expulsion is low. Most adverse events possibly delaying IUD insertion
occur early. Based on timing of adverse events in the control group, IUD insertion at approximately 2 weeks after completed MTOP seems optimal.
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Several cohort studies have shown that postabortion use
of long-acting reversible methods of contraception, and
especially that of intrauterine contraceptive devices (IUDs),
is associated with reduced incidence of recurrent unintended
pregnancy [1–4].
According to international guidelines, an IUD can be
safely inserted at the time of surgical termination of
pregnancy (TOP) or after medical termination of pregnancy
(MTOP) when, with reasonable certainty, the woman is no
longer pregnant [5–7]. Immediate insertion of an IUD at the
time of surgical TOP leads to a higher overall rate of use
compared with delayed insertion [8,9]. This is explained in
part by the high percentage of women not attending the
scheduled follow-up visit [4,10].
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dominant method of early abortion in several countries. In
2014, 95%of all induced abortionsweremedical in Finland, and
the figure was 51% in England and Wales [11,12]. In 2015, the
figures were 91% in Sweden, 88% in Norway and 81% in
Scotland [13–15]. In the US, the corresponding figure in 2011
was 23% [16]. MTOP is associated with a rate of up to 20% of
early adverse events, some of which may interfere with the
initiation of intrauterine contraception [17], although in several
studies, early IUD insertion between 1 to 4 weeks following
MTOP has proven to be safe and effective [1,18–20]. However,
the overall success of IUD provision following MTOP and the
factors affecting it have not been assessed in large-scale trials.
We have undertaken a randomized controlled clinical trial
(RCT) evaluating the long-term effects of routine provision of
IUD [either the levonorgestrel-releasing intrauterine system
(LNG-IUS) or a copper IUD (Cu-IUD)] in association with
first-trimester TOP versus the practice of initiating oral
contraceptives at the time of TOP with the plan of later
provision of IUD [21].We found that the incidence of recurrent
unintended pregnancy was significantly reduced among
women randomized to early IUD provision (intervention
group) already during the first year after the index abortion [21].
The present work is a subgroup analysis of the
above-mentioned RCT. We assessed the success of early
(i.e., between 1 and 4 weeks) initiation of intrauterine
contraception following first-trimester MTOP and the factors
that may interfere with it. Second, we analyzed all adverse
events and complications — those related to MTOP itself
(infection, heavy bleeding and incomplete abortion) and
their timing and those related to IUD insertion (infection,
expulsion, unscheduled visits) within 3 months after MTOP.2. Materials and methods
2.1. Study population
This study was performed in collaboration with Helsinki
University Hospital and the City of Helsinki. The inclusion
criteria were residence in Helsinki, age ≥18 years,
first-trimester pregnancywith desire to terminate it, acceptance
of intrauterine contraception and willingness to participate and
to sign the informed consent form. The exclusion criteria were
contraindications to intrauterine contraception, such as uterine
anomaly, acute genital infection or cytological findings in Pap
tests requiring further investigation.
The study protocol has been described in detail previously
[21]. In brief, in the primary study, 751 women were
randomized into two groups to assess the effects of
intrauterine contraception initiated in association with TOP
[either medical (n=606) or surgical (n=142)] on the need of
subsequent TOP. Three women decided to continue with the
pregnancy after randomization.
Following MTOP, the intervention group received an IUD
at a follow-up visit including clinical and ultrasonographic
examination at 1–4 weeks after MTOP. A follow-up visit wasscheduled at 3 months after TOP to ensure acceptance of the
method and correct location of the IUD by visualizing the
strings. If the strings were not detected or appeared to be too
long, vaginal ultrasonography was arranged.
Women in the control group received oral contraceptives for
immediate postabortion contraception. They were advised to
schedule a follow-up visit at 2–4weeks to verify the outcome of
TOP (serum hCG measurement) and for further contraceptive
provision (including IUD insertion) at the primary healthcare
services of the City of Helsinki. The IUD insertions occurring
within 3 months after the abortion were verified using the
electronic patient files of the City of Helsinki.
All procedures, including follow-up of the control group,
were performed according to Finnish guidelines on induced
abortion [22]. All women were screened for Chlamydia
trachomatis infection prior to TOP.
All study participants were advised to contact the study
hospital in cases of diagnosed or suspected TOP-related
complications. The follow-up visits including the planned
IUD insertions were performed by the study physicians.
Women with unscheduled hospital visits were mainly
examined by physicians on duty. The study hospital is in
charge of the abortion care and emergency gynecological
services in the Helsinki metropolitan area. In addition, the
electronic database of the hospital is comprehensive and
covers all medical specialties.
All additional visits to the hospital within 3months after TOP
were evaluated and analyzed. Unsuccessful MTOPwas defined
as continuing pregnancy with a living fetus. Cases of missed
abortion or suspected residual tissue were analyzed according to
the type of treatment provided (surgical evacuation, adminis-
tration of misoprostol or expectant management). Clinically
diagnosed genital infections were defined by purulent discharge
and/or uterine tenderness with or without fever and classified
into those treated with oral or intravenous antibiotics.
Complete IUD expulsion was defined as a totally expelled
device and partial expulsion as IUD displacement ofmore than
15 mm from the uterine fundus in vaginal ultrasonography. A
new device was offered in all cases of IUD expulsion.
2.2. Ethics approval
The study was approved by the Ethics Committee of the
Hospital District of Helsinki and Uusimaa (HUS 260/13/03/
03/2009), as well as the City of Helsinki (10–1138/054), and
it was registered at www.clinicaltrials.gov (NCT01223521).
2.3. Statistical analysis
Adverse events and complications after MTOP and their
timing were analyzed on an intention-to-treat (ITT) basis.
Assessment of complications related to early provision of an
IUD (up to 4 weeks) was performed on a per-protocol (PP)
basis. Statistical analyses were performed using IBM SPSS
statistics software Version 23.0 (IBM Corp., Armonk, NY,
USA). The chi-square test was used to evaluate possible
differences in the incidence of various complications
able 1
emographics of the study groups (ITT basis). The data are reported as
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calculate odds ratios (ORs) with a 95% confidence interval
(95% CI). To analyze the cumulative survival ratios
regarding timing of complications or adverse events, the
Kaplan–Meier model was used.ge [years (mean, SD)] 27.7 (6.40) 28.1 (6.51) 0.40
arital status
Married 58 (18.9) 42 (14.0) 0.21
Cohabitating 83 (27.0) 78 (26.1)
Single 166 (54.1) 179 (59.9)
egular/Daily smoking 153 (49.8) 152 (51.0) 0.77
hlamydia trachomatis at the time
of abortion
8 (2.6) 6 (2.0) 0.62
uration of pregnancy at the time
of abortion [days (mean, SD)]
57.5 (11.1) 56.0 (11.3) 0.09
42 days 14 (4.6) 17 (5.7) 0.73
3–63 days 215 (70.0) 212 (70.9)
4–84 days 78 (25.4) 70 (23.4)
revious pregnancies
Primigravid 98 (31.9) 100 (33.4) 0.69
History of induced abortion(s) 139 (45.3) 120 (40.3) 0.21
Parous 148 (48.2) 133 (44.6) 0.383. Results
Altogether 606 women undergoing MTOP (Fig. 1) were
included in the present analysis. In 378 cases (62.4%) MTOP
was performed using self-administration of misoprostol at
home. The characteristics of the participants are presented in
detail in Table 1.
In the intervention group, a total of 280 (91.2%) women
received an IUD, whereas the corresponding number in the
control group was 72 [24.1%, OR (95% CI) = 32.7
(20.3–52.6)]. The majority of the intervention group [n=234
(76.2%)] had an IUD insertion within 4 weeks after MTOP, as
planned initially. Later insertions [n=46 (15.0%)] were due to
suspected residual tissue and/or infection (n=43) or nonatten-
dance at the initially scheduled visit (n=3). In the control group
altogether, 8 (2.7%) women received the IUD within 4 weeks
and 64 (21.4%) between 1 and 3 months. The differences in
comparison to the intervention group were significant [OR
(95% CI) = 116.6 (55.1–246.8) and 0.647 (0.426–0.982),
respectively].
Twelve women in the intervention group received an IUD
in association with surgical evacuation because of residual
tissue and were therefore excluded from the PP analysis. In
the intervention group, 222 women and, in the control group,
297 women were included in the PP analysis. Of the 222
women in the intervention group, 204 (91.9%) chose the
LNG-IUS and, 18 (8.1%), the Cu-IUD.Medical TO
n=606 
Intervention group 
Drop outs Received IUD
n=280
IUD later IUD within 4  
weeks, n=234 






















3.1. Postabortion adverse events and complications and
their timing
During the 3-month follow-up period, 43 women had an
unscheduled visit (Table 2) because of bleeding [20 (6.5%)
in the intervention group and 23 (7.7%) in the control group,
p=.572]. Heavy bleeding was treated by means of surgical
evacuation in 9 (2.9%) versus 11 (3.7%) women, respec-
tively (p=.607). However, only 5 (0.8%) women received
blood transfusion; [2 (0.7%) in the intervention group and
3 (1.0%) in the control group, p=.632]. Nineteen women
(45.2%) contacted the hospital because of bleeding within
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Adverse events/complications within 3 months after MTOP in the study groups (ITT basis). The data are reported as n (%) unless stated other vice.
Variable Intervention group (n=307) Control group (n=299) OR (95% CI)
Adverse event/complication judged to require intervention 85 (27.7) 38 (12.7) 2.63 (1.72–4.01)
Intervention within 14 days after abortion 20 (6.5) 23 (7.7) 0.84 (0.45–1.56)
Intervention between 2 and 4 weeks (15–28 days) 59 (19.2) 7 (2.3) 9.92 (4.45–22.12)
Intervention between 4 and 6 weeks (29–42 days) 5 (1.6) 6 (2.0) 0.81 (0.24–2.68)
Intervention between 6 weeks and 3 months (43–90 days) 1 (0.3) 2 (0.7) 0.49 (0.04–5.38)
Extra visit due to bleeding 20 (6.5) 23 (7.7) 0.83 (0.45–1.56)
Heavy bleeding 11 (3.6) 15 (5.0) 0.70 (0.32–1.56)
- treated by blood transfusion 2 (0.7) 3 (1.0) 0.65 (0.11–3.90)
- treated by surgical evacuation 9 (2.9) 11 (3.7) 0.79 (0.32–1.94)
Time between the abortion and visit due to/dg of bleeding [days, (mean ± SD)] 16.2 (12.7) 19.2 (19.3)
Infection 29 (9.4) 17 (5.7) 1.73 (0.93–3.22)
- treated by intravenous antibiotics 10 (3.3) 9 (3.0) 1.08 (0.43–2.71)
- treated by per oral antibiotics 19 (6.2) 8 (2.7) 2.40 (1.03–5.57)
Time between the abortion and diagnosis of/visit due to infection [days, (mean ± SD)] 16.8 (9.6) 15.8 (15.3)
Residual tissue 72 (23.5) 30 (10.0) 2.75 (1.73–4.35)
- treated by means of surgical evacuation 40 (13.0) 24 (8.0) 1.72 (1.01–2.93)
- treated by means of additional misoprostol 52 (16.9) 9 (3.0) 6.57 (3.18–13.60)
- waiting 4 (1.3) 4 (1.3) 0.97 (0.24–3.93)
Treatment within14 days 14 (19.4) 18 (60.0) 0.75 (0.36–1.53)
2–4 weeks 55 (76.4) 7 (23.3) 9.10 (4.07–20.35)
4–6 weeks 3 (4.2) 4 (13.3) 0.73 (0.16–3.28)
6 weeks–3 months 0 1 (3.3) –
Time between abortion and visit due to/diagnosis of residual tissue [days, (mean ± SD)] 17.1 (6.7) 14.9 (12.9)
Missed abortion 2 (0.7) 4 (1.3) 0.48 (0.09–2.66)
Ongoing pregnancy 1 (0.3) 0 –
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in the intervention group and 17 (5.7%) in the control group
received antibiotics because of clinically diagnosed infec-
tion (p=.081) (Fig. 2A). Infection treated with intravenous
antibiotics occurred in 10 (3.3%) and 9 (3.0%) cases in the
intervention and control groups, respectively (p=.861).
There were 19 (6.2%) and 8 (2.7%) cases of infection
treated with oral antibiotics in the intervention and control
groups (p=.036), respectively.
Residual tissue was suspected in 72 (23.5%) and 30 (10.0%)
cases in the intervention and control groups, respectively
(pb.001) (Fig. 2B). Treatment with additional misoprostol was
performed in 52 (16.9%) versus 9 (3.0%) women (pb.001). Of
the cases of suspected residual tissue, 14 (19.4%) in the
intervention group and 18 (60.0%) in the control group were
detected within 14 days after TOP. Surgical evacuation of
residual tissue was performed in 40 (13.0%) versus 24 (8.0%)
cases, respectively (p=.045). The cumulative proportions of
women who did not undergo surgical evacuation were 79.7%
versus 84.2%, p=.032.3.2. Complications associated with IUD insertion
There were no cases of uterine perforation or bleeding
requiring blood transfusion related to IUD insertion in the
intervention group. Five women received antibiotics after
IUD insertion, one of whom received the IUD 2 weeks after
MTOP during surgical evacuation of residual tissue. She was
later diagnosed with persistent residual tissue and was treatedby surgical reevacuation and intravenous antibiotics 1 week
after IUD insertion.
During the 3-month follow-up period, there were 12 IUD
expulsions in all (12/222; i.e., 5.4%) among women who
received the IUD according to the study protocol in the
intervention group (PP analysis). Of these, 7 were partial and
5 total. We have no data concerning the possible IUD
expulsions in the control group.
Three women belonging to the control group that had
been fitted with an IUD returned to the hospital for
consultation during the 3-month follow-up, two because of
bleeding and one because of pain.
Analysis of the potential risk factors of IUD expulsion in
the intervention group revealed that uterine sound measure,
previous pregnancy or parity and body mass index did not
correlate with the incidence of expulsion. Longer duration of
gestation was associated with an elevated risk of expulsion.
Surprisingly, thickness of intrauterine content prior to IUD
insertion seemed to inversely correlate with the rate of
expulsion (Supplementary Table 3).4. Discussion
We found that when provided as part of the abortion service,
more than 75% of the planned early IUD insertions were carried
out as scheduled following first trimester MTOP. Including the
cases with a minor delay, the figure was more than 90%.
Approximately 15%of the planned insertionswere rescheduled,
Fig. 2. (A) Cumulative proportion of subjects in both study groups without
infection. (B) Cumulative proportion of subjects in both study groups
without suspected residual tissue.
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in ultrasonography. The rates of expulsions (5%) or
complications following early IUD insertion were low and
similar to those reported following insertion at the time of
surgical TOP [23]. However, when the IUD was provided
at the primary health care, insertion within 3months took place
in only 24% of the cases. The reasons for the difference
are likely to be associated with both patient and healthcare
system-related factors.
The goal of the primary RCT is to compare the long-term
(5-year follow-up) effects of routine provision of an IUD at the
time of TOP to the current practice of postabortion contracep-
tion. Therefore, also the early follow-up protocol was different.
Nevertheless, the randomized design of the study with different
follow-up protocols also proved to be a strength regarding
diagnosis and treatment of adverse events addressed in the
present subanalysis. In addition, we were reliably able to assess
all complications requiring hospital-based medical attention.
The shortcomings of the study include the fact that the
diagnostic criteria for the various adverse eventswere variable.
In addition, other than IUD insertions, we had limited
information concerning the care at the primary health care.
Moreover, the study was designed as a contraceptive trial andpowered according to the expected rate of subsequent TOP
during the follow-up period. Therefore, rare outcomes such as
uterine perforation cannot be reliably assessed.
As observed previously [17], a high number of minor
adverse events following first-trimester MTOPwas seen in the
present study, too. In addition, the rate of complications treated
by surgical evacuation, intravenous antibiotics or blood
transfusion was relatively high (19.9% in the intervention
group and 15.7% in the control group; p=.182). Corresponding
figures derived fromFinnish national health registries revealed
considerably lower rate of postabortion surgical evacuation
and use of antibiotics [17]. The high rate of postabortion
interventions seen in the present study is likely to be associated
with the investigational nature of the study, with scheduled
additional study visits in the intervention group and overall
easier access to additional consultation.
Follow-up practices vary after early MTOP. Based on the
results of a randomized study by Fiala et al., Finnish guidelines
on induced abortion recommend verification of abortion
outcome by means of serum hCG measurement 2–3 weeks
after TOP [22,24]. In the present study, women randomized to
the control group underwent the recommended follow-up in
primary healthcare, whereas the intervention group attended
the IUD insertion visit at 1–4 weeks as well as the 3-month
check-up visit at the study hospital.
As reported previously, the use of ultrasonography at the
follow-up visit significantly increased diagnosis of suspected
(and most likely clinically meaningless) residual tissue [25].
This was seen despite the fact that all examinationswere carried
out by investigators with significant experience in MTOP. The
use of ultrasonography resulted in an increased rate of
intervention, especially administration of misoprostol, in the
intervention group. It is likely that many of these treatments
were unnecessary, potentially causing harm for these women.
Thus, even if ultrasonography is useful when missed abortion
or on-going pregnancy is suspected, routinely performing
ultrasound shortly afterMTOP can lead to inaccurate diagnostic
impressions [25,26].
In addition to the above, the diagnosis of genital infections
and subsequent use of orally administered antibiotics was
higher in the intervention group. In this group, one third of the
infections were diagnosed before and half at the planned IUD
insertion visit. However, the number of women receiving
intravenous antibiotics was similar in the two groups.
The rate of IUDexpulsion (most cases ofwhichwere partial)
during the 3-month follow-up period was 5.4%. Somewhat
higher figures (7–11%) during 6 months of follow-up have
been reported following early (1–4 weeks) insertion after early
medical abortion [18,27]. The corresponding figure following
IUD insertion at the time of surgical evacuation has been 5%
[23]. Thus, early IUD insertion afterMTOP is associated with a
rate of expulsion similar to that after insertion at the time of
surgical TOP.
With the small number of expulsions in our study, we
have limited power to make conclusions concerning the risk
factors of expulsion. However, our findings are in agreement
262 E. Pohjoranta et al. / Contraception 95 (2017) 257–262with those of Sääv et al. concluding that endometrial
ultrasonographic findings have a poor predictive value in
estimating the risk of IUD expulsion following MTOP [18].
Our findings, as well as those reported previously [18,20],
support a pragmatic approach to early IUD provision after
MTOP. Following verification of complete abortion (preferably
by hCG measurement) in the absence of clinically diagnosed
complications, an IUD can be safely inserted at 1–4 weeks after
MTOP. Provision of IUD as an integral part of abortion care and
by the same organization providing the abortion seems
beneficial. Based on the timing of complications observed,
especially in the control group, IUD insertion within 2 weeks
after TOP may be optimal. On the other hand, a delay in
initiation of contraception is associated with a higher rate of
nonattendance at follow-up visits as well as risk of future
unintended pregnancy [20,21]. Thus, early time-pointsmay also
be important in order to optimize compliance as regards
contraceptive initiation and continuation. Overall, the data
encourage the development of well-coordinated fast-tract
services aimed at early provision of intrauterine contraception
following MTOP.
Supplementary data to this article can be found online at
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